CRDL Stock Chart & Stats
$1.51
-$0.03(-2.19%)
At close: 4:00 PM EST
$1.51
-$0.03(-2.19%)
Day’s Range― - ―
52-Week Range$0.88 - $1.71
Previous Close$1.33
Volume248.87K
Average Volume (3M)701.45K
Market Cap
$117.20M
Enterprise Value$144.20M
Total Cash (Recent Filing)$27.67M
Total Debt (Recent Filing)$116.41K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 17, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding115,272,240
10 Day Avg. Volume564,759
30 Day Avg. Volume701,452
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.85K
Enterprise Value/Ebitda-4.09
Forecast
1Y Price Target
$8.50Price Target Upside462.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong SolvencyExtremely low debt reduces refinancing and solvency risk, giving management durable financial optionality. For a clinical-stage biotech, minimal leverage preserves flexibility to fund trials via equity, partnerships, or asset sales without imminent debt pressure, a multi-month advantage.
Focused Clinical-stage PipelineA concentrated pipeline targeting anti-inflammatory and anti-fibrotic cardiovascular indications gives a clear strategic focus. Two differentiated candidates (CardiolRx, CRD-38) create multiple clinical milestones that can de-risk the program over months and support long-term value creation if trials progress.
Narrowing Cash Outflows TrendAn improving cash burn trajectory suggests operating discipline and modest runway extension, reducing near-term financing frequency. While FCF remains negative, sustained reduction in outflows is a durable operational improvement that lessens execution risk over the next several months.
Bears Say
Pre-revenue With Sizable LossesBeing pre-revenue and consistently loss-making means the business lacks internal cash generation to fund development. This structural profile creates sustained dependency on external capital and elevates execution risk until commercialization or recurring revenue is achieved, a multi-month concern.
Heavy Cash Burn And Funding RiskLarge negative operating and free cash flow imply ongoing external financing needs and potential dilution. Over a 2-6 month horizon, high burn plus volatile FCF growth means material risk that the company must secure capital or partnerships, which can constrain strategic choices and timing of trials.
Equity Erosion & Negative ReturnsDeclining equity and negative ROE reflect ongoing value erosion from losses, weakening the balance sheet buffer. This structural deterioration reduces resilience to setbacks and limits capacity to absorb higher spending or trial delays without raising capital, elevating medium-term financial fragility.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was $0.88 and its highest was $1.71 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $117.20M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 35 days.
How were Cardiol Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 115,272,240 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (462.91% Upside)
$8.50 (462.91% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.8%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.90%
12-Months-Change
Fundamentals
Return on Equity
-229.16%
Trailing 12-Months
Asset Growth
27.24%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
$8.50
▲(462.91% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Ownership Overview
2.25% Insiders
0.05% Mutual Funds
0.10% Other Institutional Investors
96.84% Public Companies and
Individual Investors